Defective activations of STAT3 Ser727 and PKC isoforms lead to oncostatin M resistance in metastatic melanoma

Journal of Pathology

Volumn 217, Issue 5, 2009, Pages 665-676

  Lacreusette, Aline ^a,b   Barbieux, Isabelle ^a,b   Nguyen, Jean Michel ^c   Pandolfino, Marie Christine ^a,b,d   Dréno, Brigitte ^a,b,d   Jacques, Yannick ^a,b   Godard, Anne ^a,b,d   Blanchard, Frédéric ^a,b,e  

^a Team 12   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c PIMESP   (France)

^d NANTES UNIVERSITY HOSPITAL   (France)

^e INSERM   (France)

Author keywords

Akt; Oncostatin M; PKC; Stage III melanoma; STAT3

Indexed keywords

INTERLEUKIN 6; ONCOSTATIN M; PROTEIN KINASE B; PROTEIN KINASE C DELTA; SERINE; SMALL INTERFERING RNA; STAT3 PROTEIN;

ARTICLE; CANCER GROWTH; CANCER RESISTANCE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LYMPH NODE; MELANOMA; MELANOMA CELL; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; HUMANS; INTERLEUKIN-6; ISOENZYMES; LYMPHATIC METASTASIS; MELANOMA; NEOPLASM STAGING; ONCOSTATIN M; PHOSPHORYLATION; PROTEIN KINASE C; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 64549124375     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2490     Document Type: Article

References (53)

1. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635-3648.
2. Chin L, Garraway LA, Fisher DE. Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev 2006;20:2149-2182.
3. Flaherty KT. Chemotherapy and targeted therapy combinations in advanced melanoma. Clin Cancer Res 2006;12:s 2366-2370.
4. Wrzesinski C, Restifo NP. Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy. Curr Opin Immunol 2005;17:195-201.
5. Krepler C, Certa U, Wacheck V, Jansen B, Wolff K, Peham- berger H. Pegylated and conventional interferon-α induce comparable transcriptional responses and inhibition of tumor growth in a human melanoma SCID mouse xenotransplantation model. J Invest Dermatol 2004;123:664-669.
6. Yu D, Thomas-Tikhonenko A. Intratumoral delivery of an interferon-Υ retrovirus-producing cells inhibits growth of a murine melanoma by a non-immune mechanism. Cancer Lett 2001;173:145-154.
7. Airoldi I, Di Carlo E, Cocco C, Taverniti G, D'Antuono T, Ognio E, et al. Endogenous IL-12 triggers an antiangiogenic program in melanoma cells. Proc Natl Acad Sci USA 2007;104:3996-4001.
8. Ozbek S, Peters M, Breuhahn K, Mann A, Blessing M, Fischer M, et al. The designer cytokine hyper-IL-6 mediates growth inhibition and GM-CSF-dependent rejection of B16 melanoma cells. Oncogene 2001;20:972-979.
9. Ouyang L, Shen LY, Li T, Liu J. Inhibition effect of Oncostatin M on metastatic human lung cancer cells 95-D in vitro andonmurine melanoma cells B16BL6 in vivo. Biomed Res 2006;27:197-202.
10. Bani MR, Rak J, Adachi D, Wiltshire R, Trent JM, Kerbel RS, et al. Multiple features of advanced melanoma recapitulated in tumorigenic variants of early stage (radial growth phase) human melanoma cell lines: evidence for a dominant phenotype. Cancer Res 1996;56:3075-3086.
11. Lu C, Rak JW, Kobayashi H, Kerbel RS. Increased resistance to oncostatin M-induced growth inhibition of human melanoma cell lines derived from advanced-stage lesions. Cancer Res 1993;53:2708-2711.
12. Lacreusette A, Lartigue A, Nguyen JM, Barbieux I, Pandolfino MC, Paris F, et al. Relationship between responsiveness of cancer cells to Oncostatin M and/or IL-6 and survival of stage III melanoma patients treated with tumour-infiltrating lymphocytes. J Pathol 2008;216:451-459.
13. Tanaka M, Miyajima A. Oncostatin M, a multifunctional cytokine. Rev Physiol Biochem Pharmacol 2003;149:39-52.
14. Boniface K, Diveu C, Morel F, Pedretti N, Froger J, Ravon E, et al. Oncostatin M secreted by skin infiltrating T lymphocytes is a potent keratinocyte activator involved in skin inflammation. J Immunol 2007;178:4615-4622.
15. Chen SH, Benveniste EN. Oncostatin M: a pleiotropic cytokine in the central nervous system. Cytokine Growth Factor Rev 2004;15:379- 391.
16. Sugaya M, Fang L, Cardones AR, Kakinuma T, Jaber SH, Blauvelt A, et al. Oncostatin M enhances CCL21 expression by microvascular endothelial cells and increases the efficiency of dendritic cell trafficking to lymph nodes. J Immunol 2006;177:7665-7672.
17. Grant SL, Begley CG. The oncostatin M signalling pathway: reversing the neoplastic phenotype? Mol Med Today1999;5:406-412.
18. Grant SL, Douglas AM, Goss GA, Begley CG. Oncostatin M and leukemia inhibitory factor regulate the growth of normal human breast epithelial cells. Growth Factors 2001;19:153-162.
19. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller- Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003;374:1 -20.
20. Lacreusette A, Nguyen JM, Pandolfino MC, Khammari A, Dreno B, Jacques Y, et al. Loss of oncostatin M receptor beta in metastatic melanoma cells. Oncogene 2007;26:881 -892.
21. Dillon SR, Sprecher C, Hammond A, Bilsborough J, Rosenfeld- Franklin M, Presnell SR, et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol 2004;5:752-760.
22. Kortylewski M, Heinrich PC, Mackiewicz A, Schniertshauer U, Klingmuller U, Nakajima K, et al. Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27/Kip1. Oncogene1999;18:3742-3753.
23. Kamaraju AK, Bertolotto C, Chebath J, Revel M. Pax3 down- regulation and shut-off of melanogenesis in melanoma B16/F10.9 by interleukin-6 receptor signaling. J Biol Chem2002;277:15132-15141.
24. Florenes VA, Lu C, Bhattacharya N, Rak J, Sheehan C, Slinger- land JM, et al. Interleukin-6 dependent induction of the cyclin dependent kinase inhibitor p21WAF1/CIP1 is lost during progression of human malignant melanoma. Oncogene1999;18:1023-1032.
25. Darnell JE Jr. Transcription factors as targets for cancer therapy. Nat Rev Cancer 2002;2:740-749.
26. Schuringa JJ, Schepers H, Vellenga E, Kruijer W. Ser727- dependent transcriptional activation by association of p300 with STAT3 upon IL-6 stimulation. FEBS Lett 2001;495:71-76.
27. Lufei C, Koh TH, Uchida T, Cao X. Pin1 is required for the Ser727 phosphorylation-dependent Stat3 activity. Oncogene 2007;26:7656- 7664.
28. Jain N, Zhang T, Kee WH, Li W, Cao X. Protein kinase C delta associates with and phosphorylates Stat3 in an interleukin-6-dependent manner. JBiolChem1999;274:24392-24400.
29. Koivunen J, Aaltonen V, Peltonen J. Protein kinase C (PKC) family in cancer progression. Cancer Lett 2006;235:1-10.
30. La Porta CA, Porro D, Comolli R. Higher levels of melanin and inhibition of cdk2 activity in primary human melanoma cells WM115 overexpressing nPKCδ. Melanoma Res 2002;12:297-307.
31. Holgado-Madruga M, Emlet DR, Moscatello DK, Godwin AK, Wong AJ. A Grb2-associated docking protein in EGF- and insulin- receptor signalling. Nature 1996;379:560-564.
32. Robertson GP. Functional and therapeutic significance of Akt deregulation in malignant melanoma. Cancer Metast Rev 2005;24:273-285.
33. Bohm M, Schulte U, Funk JO, Raghunath M, Behrmann I, Kortylewski M, et al. Interleukin-6-resistant melanoma cells exhibit reduced activation of STAT3 and lack of inhibition of cyclin E-associated kinase activity. J Invest Dermatol 2001;117:132-140.
34. Li Z, Metze D, Nashan D, Muller-Tidow C, Serve HL,Poremba C, et al. Expression of SOCS-1, suppressor of cytokine signalling-1, in human melanoma. J Invest Dermatol 2004;123:737-745.
35. Komyod W, Bohm M, Metze D, Heinrich PC, Behrmann I. Constitutive suppressor ofcytokine signaling 3 expression confers a growth advantage to a human melanoma cell line. Mol Cancer Res 2007;5:271 -281.
36. + cytotoxic T lymphocyte clone in the bulk culture of tumor-infiltrating lymphocytes from a melanoma patient: cytotoxic activity and T cell receptor gene rearrangements. Eur J Immunol 1990;20:825-831.
37. Blanchard F, Kinzie E, Wang Y, Duplomb L, Godard A, Held WA, et al. FR901228, an inhibitor of histone deacetylases, increases the cellular responsiveness to IL-6 type cytokines by enhancing the expression of receptor proteins. Oncogene2002;21:6264-6277.
38. Zhang XD, Wu JJ, Gillespie S, Borrow J, Hersey P. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin. Clin Cancer Res 2006;12:1355-1364.
39. Oka M, Kikkawa U. Protein kinase C in melanoma. Cancer Metastasis Rev 2005;24:287-300.
40. Park YJ, Park ES, Kim MS, Kim TY, Lee HS, Lee S, et al. Involvement of the protein kinase C pathway in thyrotropin- induced STAT3 activation in FRTL-5 thyroid cells. Mol Cell Endocrinol 2002;194:77-84.
41. Thyrell L, Hjortsberg L, Arulampalam V, Panaretakis T, Uhles S, Dagnell M, et al. Interferon-α-induced apoptosis in tumor cells is mediated through the phosphoinositide 3- kinase/mammalian target of rapamycin signaling pathway. J Biol Chem 2004;279:24152-24162.
42. Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Leung E, et al. A3 adenosine receptor activation inhibits cell proliferation via phosphatidylinositol 3-kinase/Akt-dependent inhibition of the extracellular signal-regulated kinase 1/2 phosphorylation in A375human melanoma cells. JBiolChem2005;280:19516-19526.
43. Stephens L, Anderson K, Stokoe D, Erdjument-Bromage H, Painter GF, Holmes AB, et al. Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation
44. ofprotein kinase B. Science 1998;279:710-714.
45. Partovian C, Simons M. Regulation of protein kinase B/Akt activity and Ser473 phosphorylation by protein kinase Calpha in endothelial cells. Cell Signal 2004;16:951-957.
46. Xia S, Forman LW, Faller DV. Protein kinase C delta is required for survival of cells expressing activated p21RAS. J Biol Chem 2007;282:13199-13210.
47. Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY, et al. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 2006;127:125-137.
48. Niu G, Bowman T, Huang M, Shivers S, Reintgen D, Daud A, et al. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 2002;21:7001-7010.
49. Wang W, Edington HD, Rao UN, Jukic DM, Land SR, Fctyone S,et al. Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNα2b. Clin Cancer Res 2007;13:1523-1531.
50. Wong LH, Krauer KG, Hatzinisiriou I, Estcourt MJ, Hersey P, Tam ND, et al. Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3Υ. J Biol Chem 1997;272:28779-28785.
51. Wellbrock C, Weisser C, Hassel JC, Fischer P, Becker J, Vet- ter CS, et al. STAT5 contributes to interferon resistance of melanoma cells. Curr Biol 2005;15:1629-1639.
52. Lu C, Sheehan C, Rak JW, Chambers CA, Hozumi N, Kerbel RS. Endogenous interleukin 6 can function as an in vivo growth- stimulatory factor for advanced-stage human melanoma cells. Clin Cancer Res 1996;2:1417- 1425.
53. Mouawad R, Khayat D, Merle S, Antoine EC, Gil-Delgado M, Soubrane C. Is there any relationship between interleukin- 6/interleukin-6 receptor modulation and endogenous interleukin- 6 release in metastatic malignant melanoma patients treated by biochemotherapy? Melanoma Res 1999;9:181-188.